郑州安图生物工程股份有限公司关于使用闲置募集资金进行现金管理的公告

Group 1 - The company plans to use idle raised funds for cash management, ensuring it does not affect the normal implementation of fundraising projects and guarantees the safety of the raised funds [3][11][19] - The investment types include structured deposits, large certificates of deposit, reverse repos, broker income certificates, and broker wealth management products, all of which are high-security and liquid principal-protected products [2][7][8] - The total investment amount will not exceed 1.4 billion yuan from publicly issued convertible bonds and 15.4 billion yuan from non-publicly issued stock [2][4][7] Group 2 - The cash management is aimed at enhancing the value of idle funds and increasing company revenue while protecting the interests of all shareholders [3][19] - The board of directors approved the cash management proposal on December 9, 2025, during the ninth meeting of the fifth board [13][30] - The cash management products will be managed by reputable financial institutions that provide principal protection, and the investment period will not exceed 12 months [8][9][30] Group 3 - The company will ensure that the cash management does not affect the normal operations and funding needs of the company [19][33] - The financial products will be recorded as trading financial assets or other current assets in the balance sheet, with interest income recorded in the profit statement [19][33] - The company will disclose cash management details in accordance with relevant regulations and guidelines [12][32]